Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Biophys Res Commun. 2001 Jan 12;280(1):115-20.

Immunomodulation of the human prion peptide 106-126 aggregation.

Author information

1
Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences, Ramat Aviv, Tel-Aviv 69978, Israel.

Abstract

Site-directed monoclonal antibodies (mAbs) may interact with their antigens, leading to stabilization, refolding, and suppression of aggregation. In the following study, we show that mAbs raised against the peptide 106-126 of human prion protein (PrP 106-126) modulate the conformational changes occurring in the peptide exposed to aggregation conditions. MAbs 3-11 and 2-40 prevent PrP 106-126's fibrillar aggregation, disaggregates already formed aggregates, and inhibits the peptide's neurotoxic effect on the PC12 cells system, while mAb 3F4 has no protective effect. We suggest that there are key positions within the PrP 106-126 molecule where unfolding is initiated and their locking with specific antibodies may maintain the prion peptide native structure, reverse the aggregated peptide conformation, and lead to rearrangements involved in the essential feature of prion diseases.

PMID:
11162487
DOI:
10.1006/bbrc.2000.4097
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center